top of page
Screenshot 2023-06-28 211429.png


Vitamin A reinvented for Neonatal & Pediatric Care



Committed to developing life-changing medicines for the most-fragile preterm infants and patients with other unmet medical needs

Screenshot 2023-06-28 211429.png

About Us

Advent Therapeutics is a late-stage neonatology and rare disease biopharmaceutical company pioneering life-changing medicines for extremely preterm infants. We are focused on addressing a very serious respiratory disease called bronchopulmonary dysplasia (BPD) which is the most common serious complication of prematurity and causes lung damage that leads to prolonged NICU stays, a range of comorbidities that can include long-term lung damage, and even death


Advent is committed to preventing and treating BPD by advancing its proprietary formulations of retinol palmitate (vitamin A) as novel metabolic and reparative therapies specifically optimized for preterm infants 


Advent’s BPD programs have been supported extensively by the National Institutes of Health (NIH) and the Commonwealth of Pennsylvania. The Company maintains laboratory and office space at the Pennsylvania Biotechnology Center (PABC) in Bucks County

Screenshot 2023-06-28 211429.png


Advent’s Metabolic & Reparative Technology

Advent has designed its proprietary water miscible vitamin A palmitate drug products for optimal administration to fragile preterm neonates. The drugs do not contain chlorobutanol (an alcohol) or other preservatives that may be of concern with respect to sensitivity or potential toxicity

Advent’s formulation of vitamin A comes in two methods of application: intramuscular (IM) and aerosolized products for use in NICUs as orphan drugs to address unmet medical needs such as BPD, retinopathy of prematurity (ROP), and acute lung injury (ALI)

Screenshot 2023-07-09 233856.png
Screenshot 2023-07-09 233919.png
Screenshot 2023-07-09 233945.png

Vitamin A plays a key role in preventing neonatal BPD 

Screenshot 2023-06-28 211429.png

Our Leadership Team

Screenshot 2023-07-09 215326.png

CEO and co-founder

  • LinkedIn

David L. Lopez, Esq., CPA

Screenshot 2023-07-09 215430.png

Head of R&D

  • LinkedIn

Craig Gelfand, PhD

Screenshot 2023-07-09 215444.png

CMO and co-founder

  • LinkedIn

Robert Segal, MD, FACP

Screenshot 2023-07-09 215418.png

Chief Medical Advisor and co-founder

  • LinkedIn

Jan Mazela, MD, PhD


Screenshot 2023-07-09 222705_edited.png
Screenshot 2023-06-28 211429.png

Neonatal BPD | serious problem with no approved therapy

Bronchopulmonary Dysplasia (BPD) is a chronic respiratory disease requiring oxygen supplementation and ventilatory support with extensive, costly stays at hospital’s Neonatal Intensive Care Unit (NICU)

BPD is the most common serious morbidity of prematurity[1]. The earlier the birth, the lower the infant’s weight , the higher the probability of BPD occurrence. BPD is strongly associated with vitamin A deficiency and is addressable with effective & safe supplementation

NIH considers BPD a severe unmet need

Screenshot 2023-07-10 002112.png
Screenshot 2023-07-10 002211.png

1 - Thébaud, B.,  et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers 5, 78 (2019)

2 - US Department of Health & Human Services, Agency for Healthcare Research and Quality (AHRQ), H-CUPnet, Rockville, MD

3 - Lapcharoensap  et al. Hospitalization costs associated with bronchopulmonary dysplasia in the first year of life. J Perinatol 40, 130–137 (2020)

4 - Bhandari A, et al., BPD Following Preterm Birth: A Model for Chronic Lung Disease and a Substrate for ARDS in Childhood. Front Pediatr. 2016 15;4:60.

Screenshot 2023-06-28 211429.png
Get a Demo

Advent Therapeutics, Inc.

Contact Us

bottom of page